What Liquidia Corp does.

We are a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases such as pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease (“PH-ILD”). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC, formerly known as RareGen.

We currently generate revenue through the sale of YUTREPIA (treprostinil) inhalation powder (“YUTREPIA”) and pursuant to a promotion agreement with Sandoz Inc. (“Sandoz”), dated as of August 1, 2018, as amended (the “Promotion Agreement”), under which we share profit derived from the sale of Sandoz’s generic treprostinil injection (“Treprostinil Injection”) in the United States.

We employ a targeted commercial field force calling on healthcare providers involved in the treatment of PAH and PH-ILD in the United States, as well as key stakeholders involved in the distribution and reimbursement of medicines to treat these patients.

Revenue and profit, by fiscal year.

More on LQDA.

• Liquidia Corp summary
• Liquidia Corp financial statements
• Liquidia Corp key metrics
• Liquidia Corp health scores and style box
• Liquidia Corp earnings
• Liquidia Corp dividends
• Liquidia Corp valuation
• Liquidia Corp ownership and insiders
• Liquidia Corp peers

Figures from Liquidia Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.